| |
| |
|
| Insider
Information: |
Mayleben Timothy M |
| Relationship: |
Director |
| City: |
Ann Arbor |
| State: |
MI |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
285,938 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$6,320,366 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
285,938 |
|
|
| Total
Value |
$6,320,366 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-2.0
|
0.0
|
| Percentage
Gain/Loss : |
 -38.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vericel Corp |
VCEL |
President and CEO, Dir... |
2011-08-08 |
133,000 |
2005-11-01 |
0 |
Premium* |
|
|
Nighthawk Radiology Holdings Inc |
NHWK |
Chief Operating Office... |
2007-12-31 |
8,165 |
|
0 |
Premium* |
|
|
Esperion Therapeutics, Inc. |
ESPR |
President & CEO, Direc... |
2020-12-30 |
122,698 |
|
0 |
Premium* |
|
|
Marinus Pharmaceuticals Inc |
MRNS |
|
2024-01-18 |
22,075 |
2015-07-16 |
0 |
Premium* |
|
|
Loxo Oncology, Inc. |
LOXO |
Director |
2018-06-08 |
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRNS |
Marinus Pharmaceuticals I... |
|
– • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,600 |
22,075 |
0 |
- |
|
| MRNS |
Marinus Pharmaceuticals I... |
|
– • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
17,475 |
0 |
- |
|
| MRNS |
Marinus Pharmaceuticals I... |
Director |
– • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
13,875 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2020-12-30 |
4 |
OE |
$2.10 |
$22,427 |
D/D |
10,700 |
122,698 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2020-03-11 |
4 |
B |
$43.00 |
$107,500 |
D/D |
2,500 |
111,998 |
2.81 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2020-02-28 |
4 |
B |
$49.00 |
$245,000 |
D/D |
5,000 |
109,498 |
2.81 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
23,150 |
104,498 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
365 |
81,348 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-11-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,950 |
81,173 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-11-06 |
4 |
B |
$36.98 |
$184,900 |
D/D |
5,000 |
83,663 |
2.81 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-09-06 |
4 |
B |
$35.25 |
$88,125 |
D/D |
2,500 |
78,663 |
2.81 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-09-04 |
4 |
B |
$33.42 |
$170,982 |
D/D |
5,000 |
76,163 |
2.81 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-08-01 |
4 |
B |
$39.56 |
$197,800 |
D/D |
5,000 |
71,163 |
2.81 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-06-28 |
4 |
B |
$46.00 |
$230,000 |
D/D |
5,000 |
66,163 |
2.81 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-03-29 |
4 |
B |
$40.00 |
$200,000 |
D/D |
5,000 |
61,163 |
2.81 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-03-20 |
4 |
B |
$43.48 |
$217,400 |
D/D |
5,000 |
56,163 |
2.81 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2019-03-14 |
4 |
B |
$48.73 |
$243,650 |
D/D |
5,000 |
51,163 |
2.81 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-06-08 |
4 |
S |
$179.55 |
$1,795,469 |
D/D |
(10,000) |
0 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-06-08 |
4 |
OE |
$20.91 |
$217,550 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
President & CEO |
• • – |
2018-01-31 |
4 |
OE |
$1.05 |
$5,325 |
D/D |
4,549 |
46,163 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2017-12-20 |
4 |
AS |
$80.49 |
$804,948 |
D/D |
(10,000) |
0 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2017-11-22 |
4 |
OE |
$20.91 |
$62,730 |
D/D |
3,000 |
13,000 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2017-11-22 |
4 |
S |
$75.85 |
$227,563 |
D/D |
(3,000) |
10,000 |
0 |
- |
|
| MRNS |
Marinus Pharmaceuticals I... |
Director |
– • – |
2017-01-17 |
4/A |
A |
$0.00 |
$0 |
D/D |
4,500 |
50,350 |
0 |
- |
|
| MRNS |
Marinus Pharmaceuticals I... |
Director |
– • – |
2016-08-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
3,300 |
45,850 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
